Role of serum proadrenomedullin in assessment of the severity and outcome of hospitalized healthcare-associated pneumonia patients
Amany Shaker a, Doaa Mostafa Gad a, Sameh Embarak a, Hany A. Labib b

Background Clinical judgment of healthcare-associated pneumonia (HCAP) represents a major concern as these fragile patients have an unusual presentation that frequently misleads severity assessment and results in poor clinical outcome. The aim of this study was to evaluate the role of proadrenomedullin (proADM) in predicting disease severity and outcome in HCAP patients in comparison with community-acquired pneumonia (CAP) patients.

Patients and methods Thirty-one HCAP patients and twenty-five CAP patients were enrolled in this study. Measurement of serum proADM level was performed in the first 24-h of admission. Assessment of severity was carried out using the CURB-65 scoring system. Finally, the outcome of the patients was assessed.

Results Serum proADM level was higher in HCAP patients than that in CAP patients, this difference was statistically significant. Also, serum proADM level increased significantly with increasing severity of HCAP patients guided by CURB-65, with a cut-off value of more than 1.8 nmol/l, with a sensitivity of 91.7%, a specificity of 95%, a positive predictive value of 91.7%, and a negative predictive value of 95%. However, a higher value (>2.9 nmol/l) was detected in HCAP patients who died, with high sensitivity and negative predictive value (100%) and low specificity (42.3%) and positive predictive value (25%).

Conclusion The use of proADM as a novel biomarker enhances the performance of the CURB-65 scoring system for risk stratification of HCAP patients.

Keywords: community-acquired pneumonia, healthcare-associated pneumonia, proadrenomedullin

Introduction Pneumonias have been classified as community-acquired pneumonia (CAP) and hospital-acquired pneumonia, and this classification is used for proper diagnosis and treatment decisions [1]. However, when pneumonia is associated with healthcare risk factors such as previous hospitalization, residing in a nursing home, receiving outpatient parental therapy, attending a hemodialysis clinic, or receiving domiciliary care, it becomes more complex [2]. The American Thoracic Society and the Infectious Disease Society of America had proposed healthcare-associated pneumonia (HCAP) as a new pneumonia classification for patients from the community who had recent contact with the healthcare system [3].

Clinical judgment of HCAP represents a major concern as these fragile patients have an unusual clinical presentation that frequently misleads severity assessment and results in poor clinical outcome [4]. Despite the latest advances in antimicrobial therapy and improved supportive care, HCAP is still a major cause of morbidity and mortality twice as higher than those observed in CAP [5]. Therefore, early identification of patients at high risk is a key point in improving their outcome. Several generic severity scoring systems have been developed to determine patients’ outcome, but they may be complicated for use in everyday practice [6]. Moreover, these scores may underestimate severity assessment in young patients and perform less well when considering outcomes such as ICU admission and mechanical ventilation (MV) [7]. Thus, biomarkers are gaining importance in improving the prognostic accuracy of clinical scores [6].

Proadrenomedullin (ADM) is a vasoactive hormone that is predominantly released by the endothelium during physiological stress and acts as a potent vasodilator with natriuretic effects [8]; moreover, it reduces endothelial permeability [9], exerts bactericidal effects [10], and downregulates proinflammatory cytokines [11].

Proadrenomedullin (proADM) is considered good for the determination of severity scores in identifying critically ill patients with CAP and is probably better than other biomarkers used such as procalcitonin and C-reactive protein [6]. In addition, it has greater discriminatory power in predicting serious complications in CAP patients than the pneumonia severity index (PSI) and CURB-65 scores [12]. These findings may be used to decide on the management of the patient, especially for patients with low severity scores and high levels of
Role of serum proadrenomedullin biomarkers, as the decision to treat these cases as outpatients should be considered [13]. Therefore, this study aimed to evaluate the role of proADM in predicting disease severity and outcome in HCAP patients compared with CAP patients.

Patients and methods

Patients

The current study was carried out at the Chest Department (hospital ward and respiratory ICU) and the Clinical Pathology Department, Zagazig University Hospitals, between December 2010 and December 2012. It included 31 HCAP patients, 20 men and 11 women, mean age 64.1 ± 9.8 years, and 25 CAP patients (with no history or clinical evidence of comorbidities), 15 men and 10 women, mean age 57.4 ± 10.9 years.

Patients were recruited according to the diagnostic criteria of CAP and HCAP.

CAP was defined by the presence of at least one respiratory symptom (cough, sputum production, dyspnea, tachypnea, pleuritic pain) plus at least one finding during auscultation (rales, crepitation), or one sign of infection (core body temperature >38.0°C, shivering, leukocyte count >10 or <4 × 10^9 cells/l) along with a new infiltrate on the chest radiograph [14].

HCAP was defined as patients admitted to the hospital (because of pneumonia) fulfilling at least one of the following [15]:

1. Hospitalization for 2 or more days in the preceding 90 days.
2. Chronic dialysis within 30 days.
3. Home wound care.
4. Home infusion therapy including antibiotics.
5. Immunosuppressive disease and/or therapy (systemic corticosteroids, immunosuppressive drugs).
6. Presence of chronic indwelling devices.

Exclusion criteria were as follows: ventilator–associated pneumonia, hospital–acquired pneumonia, and suspected or known aspiration pneumonia [5].

Methods

All the patients studied were subjected to the following:

1. Thorough assessment of medical history, with a focus on other comorbidities.
2. Full clinical examination (general and local examination).
3. Plain chest radiography (posteroanterior and lateral views).
4. Routine laboratory investigations:
   (a) Complete blood picture.
   (b) Liver functions.
   (c) Kidney functions.
   (d) Blood sugar testing.
5. The CURB-65 scoring system was used for assessment of severity: ICU admission was considered if patients fulfilled more than two criteria of the CURB-65 scoring system, whereas ward admission was considered if patients fulfilled only two criteria [confusion, blood urea nitrogen >7 mmol/l (Blood urea nitrogen (BUN) >19.6 mg/dl), respiratory rate >30 breaths/min, blood pressure <90 mmHg systolic or <60 mmHg diastolic, age ≥65 years] [16].
6. Measurement of serum biomarker proADM level was performed in the first 24 h of the admission. Seven milliliter venous blood samples were obtained and collected in tubes containing EDTA. After centrifugation, they were kept frozen at −80°C until assayed. ProADM was measured using the enzyme immunoassay kit, which is designed to detect a specific peptide and its related peptides on the basis of the principle of competitive enzyme immunoassay (DRG International Inc., USA). The normal reference range is 0.33 ± 0.7 nmol/l [17].
7. Assessment of duration of hospital stay and occurrence of complication(s), for example, septic shock, acute respiratory distress syndrome (ARDS), empyema, or need for MV.

**Septic shock**: defined as the presence of systemic inflammatory response syndrome, documented by infection or positive blood culture and organ dysfunction, hypoperfusion, or sepsis-induced hypotension refractory to adequate fluid resuscitation or the use of inotropics or vasopressor support [18].**ARDSe**: acute onset, bilateral infiltrates on chest radiographs, pulmonary artery occlusion pressure less than 18 mmHg, if measured, or absence of clinical signs of left atrial hypertension, and presence of PaO2/FiO2 less than 200 mmHg [19].

8. Assessment of final outcome, which was either discharge or death.

Statistical analysis

Statistical analysis was carried out using the SPSS statistical software package (version 19; SPSS Inc., Chicago, Illinois, USA).

Data were presented as mean ± SD for quantitative continuous data, comparison between the means of several groups was performed by one-way analysis for variance (F-test), and post-hoc analysis (LSD) was carried out.
Table 1 Demographic data of the studied patients

| Parameters                      | HCAP (n = 31) | CAP (n = 25) | P-value |
|---------------------------------|---------------|-------------|---------|
| Age (mean ± SD) (years)         | 64.1 ± 9.8    | 57.4 ± 10.9 | 0.02    |
| Sex (male/female)               | 20/11         | 15/10       | 0.70    |
| Current smokers (n [%])         | 11 (35.5)     | 13 (52.0)   | 0.21    |
| Systolic BP (mmHg)              | 103.2 ± 22.7  | 115.5 ± 22.3| 0.04    |
| Diastolic BP (mmHg)             | 64.03 ± 11.34 | 73.72 ± 11.85| 0.04    |
| Temperature (°C)                | 37.5 ± 1.6    | 38.6 ± 0.6  | 0.003   |
| Respiratory rate (breaths/min)  | 32.7 ± 3.2    | 30.7 ± 3.1  | 0.025   |
| Confusion (n [%])               | 12 (38.7)     | 5 (20)      | 0.046   |
| ICU admission (n [%])           | 19 (61.3)     | 8 (32)      | 0.03    |

BP, blood pressure; CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia.

Table 2 Risk factors of healthcare-associated pneumonia patients

| Risk factors                             | N (%) |
|------------------------------------------|-------|
| Home wound care                          | 4 (12.9) |
| Hospitalization for ≥2 days in previous 90 days | 12 (38.7) |
| Immunosuppressive diseases               | 7 (22.6) |
| Immunosuppressive therapy                | 8 (25.8) |

Table 3 Laboratory data of the studied groups

| Parameters                      | HCAP (n = 31) | CAP (n = 25) | P-value |
|---------------------------------|---------------|-------------|---------|
| WBC (mean ± SD) (×10⁹ cells/l)  | 9.1 ± 3.1     | 13.75 ± 3.35| 0.001   |
| Creatinine (mean ± SD) (mg/dl)  | 2.1 ± 0.7     | 0.6 ± 0.3   | 0.001   |
| BUN (mean ± SD) (mg/dl)         | 37.8 ± 12     | 26.5 ± 5.8  | 0.035   |
| ProADM (mean ± SD) (nmol/l)     | 3.52 ± 1.0    | 1.18 ± 0.35 | 0.001   |

CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia; proADM, proadrenomedullin; WBC, white blood cell.

Table 4 Patients’ outcome during hospitalization

| Parameters                      | HCAP (n = 31) | CAP (n = 25) | P-value |
|---------------------------------|---------------|-------------|---------|
| Duration of hospital stay (mean ± SD) (days) | 17.6 ± 4.8 | 9.3 ± 3.2 | 0.001   |
| Occurrence of complications (n [%]) |                    |              |         |
| Empyema                          | 4 (12.9)      | 0 (0.0)     | –       |
| Septic shock                     | 2 (6.45)      | 0 (0.0)     | –       |
| ARDS                             | 3 (9.67)      | 0 (0.0)     | –       |
| Need for MV                      | 10 (32.35)    | 2 (8.0)     | 0.027   |
| Mortality (n [%])                | 5 (16.12)     | 0 (0.0)     | –       |

ARDS, acute respiratory distress syndrome; CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia; MV, mechanical ventilation.

Qualitative data were presented as number and percentage, and association was tested using the χ²-test.

The receiver operating characteristic (ROC) curve was used to predict cut-off values of severity and mortality from HCAP and area under the curve; 95% confidence interval was used. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated, and κ measurement was performed. P-value less than 0.05 was considered significant.

Results

Table 1 shows the demographic data of all the patients enrolled in this study. There were statistically significant differences between HCAP and CAP patients in age, blood pressure (systolic and diastolic), temperature, respiratory rate, and presence of confusion. Also, HCAP patients showed higher number of ICU admissions than CAP patients.

Table 2 shows the risk factors of HCAP patients, indicating that hospitalization of 2 or more days in the previous 90 days was the most common risk factor in these patients.

Table 3 shows a statistically highly significant increase in the proADM level (nmol/l) in the HCAP group than that in the CAP group (P = 0.001). Also, there was a statistically significant increase in BUN (mg/dl) and creatinine (mg/dl) levels in the HCAP group than that in the CAP group (P = 0.035 and 0.001, respectively). However, a statistically highly significant decrease in the white blood cell counts (×10⁹/l) was detected in the HCAP group than in the CAP group (P = 0.001).

Table 4 shows the outcome of both groups during hospitalization. Patients with HCAP were significantly more likely to develop complications (empyema, septic shock, ARDS) and more in need of MV with a prolonged duration of hospital stay than patients with CAP (P < 0.05). Mortality occurred only in HCAP patients.

Table 5 shows a highly significant increase in the serum level of proADM (nmol/l) on admission with increasing severity of CAP and HCAP assessed by CURB-65 (P = 0.0001).

Table 5 Comparison between levels of proadrenomedullin (nmol/l) among patients of both groups in the severity of pneumonia (measured by CURB-65)

| Pneumonia severity studied groups | CURB-65 score ≤2 | CURB-65 score >2 | P-value |
|-----------------------------------|------------------|------------------|---------|
| N (%)                             | ProADM (nmol/l)  | N (%)            | ProADM (nmol/l)  |       |
| HCAP (n = 31)                     | 12 (38.71)       | 2.3 ± 0.5        | 19 (61.29)       | 4.3 ± 0.4 | 0.0001 |
| CAP (n = 25)                      | 17 (68)          | 0.99 ± 0.21      | 8 (32)           | 1.6 ± 0.19 | 0.0001 |

CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia; proADM, proadrenomedullin.
Table 6 shows a statistically significant increase in the serum proADM level (nmol/l) in patients who died than that in survivors in the HCAP group ($P = 0.01$).

Figures 1 and 2 show a ROC analysis in which sensitivities were calculated in HCAP patients who had severe pneumonia (assessed by the CURB-65 score) and who died during the study. The area under the curve, PPV, NPV, sensitivity, and specificity for cut-off levels of serum proADM (nmol/l) were calculated and are shown in Tables 7 and 8. A serum proADM level more than 1.8 nmol/l had good sensitivity and PPV (91.7% for each), and high specificity and NPV (95% for each) in predicting severe disease among HCAP patients ($P = 0.001$), whereas a serum proADM level more than 2.9 nmol/l had very high sensitivity and NPV (100% for each), but low specificity (42.3%) and low PPV (25%) in predicting mortality among HCAP patients ($P = 0.03$).

**Discussion**

Physicians dealing with patients with pneumonia in the emergency department should be aware that a considerable number of patients presenting with pneumonia may have HCAP and require a targeted approach when deciding on empirical antibiotic therapy [1]. Although the PSI and CURB-65 scores are the most widely used predictive scoring systems, each has advantages and limitations. The PSI score has primarily been developed to identify patients with a low risk of mortality who could be treated as outpatients [20]; however, this system can potentially overestimate the severity of illness in elderly patients, especially those with comorbidities. In contrast, the CURB-65 score has been developed to enable easy identification of patients with severe illness with a high mortality risk [21], but it is not ideal for identification of patients with multiple comorbidities [22].

Therefore, there is growing interest in the search for biomarkers enabling improvement in risk stratification alone or in combination with clinical prognostic scores [23]. Previous studies have reported mid-regional proADM as a promising marker as...
it has multiple tissue sites of action and multiple functions including vasodilatory, anti-inflammatory, and antimicrobial activities [24]. Furthermore, the use of proADM in combination with CURB-65 was found to reduce the initial length of stay compared with the CURB-65 score alone in patients with CAP [25].

Clinical management of HCA represented a major concern as these fragile patients usually show an unusual clinical presentation that frequently misleads severity assessment and results in poor clinical outcomes [4]. Therefore, this study was carried out to evaluate the role of proADM in assessing disease severity and outcome in HCAP patients.

In this study, there was a statistically significant increase in age (years) in the HCAP group than in the CAP group (Table 1). Similar results were obtained by Kollef et al. [26], Carratala et al. [1], Polverino and Torres [15], and Attridge et al. [3], who reported that the clinical presentation of HCAP patients is frequently associated with advanced age, presence of neurological disorders, presence of multiple chronic comorbidities, and/or receiving medicare than patients with CAP.

Also, there were statistically significant differences between the CAP and HCAP groups in all parameters of the clinical data (systolic and diastolic blood pressure, temperature, conscious level, and respiratory rate) (Table 1). These results are not in agreement with those of Carratala et al. [1] and Polverino and Torres [15], who reported that extrapulmonary manifestations including mental confusion were more frequent in the HCAP group. However, Polverino et al. [4] observed, from their study, that there was no difference between CAP and HCAP patients in the data of clinical presentation.

The current study found a statistically highly significant increase in the serum level of proADM in the HCAP group than that in the CAP group (Table 3). Our results were in agreement with those of Polverino et al. [4], who reported that serum proADM and procalcitonin were higher in the HCAP group than in the CAP group on hospital admission.

For patients’ outcome, a statistically highly significant increase was observed in HCAP patients than in CAP patients in the duration of hospital stay. Also, there was a statistically significant increase in the development of complications (empyema, septic shock, and ARDS) and need for MV in the HCAP group than in the CAP group. Mortality occurred only among HCAP patients (Table 4).

Our results are in agreement with the results of Kollef et al. [26], Carratala et al. [1], Micek et al. [2], Carrabba et al. [5], and Joong et al. [22], who reported that (i) HCAP patients also had comorbid conditions (chronic obstructive lung disease, chronic heart disease, cerebrovascular disease, and cancer), leading to increased severity of pneumonia, (ii) increased number of risk factors in the same HCAP patients were positively correlated with more exposure to complications and mortality, (iii) underestimation of the HCAP pathogen as they were likely to be multidrug-resistant organisms (methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa), and their treatment with an inappropriate initial antibiotic regimen would lead to more complications, increased duration of hospital stay, and higher mortality rate.

In contrast to our results, Attridge et al. [3] reported that mortality rates and length of hospital stay were lower for HCAP patients. This discrepancy may be because theirs was a retrospective cohort study and critically ill patients were excluded from their study.

In the current study, serum proADM levels increased with increasing severity of the disease in both CAP and HCAP groups (when assessed by CURB-65), and this increase was statistically highly significant in both groups (Table 5).

Our results are not in agreement with those of Schuetz et al. [12], Albrich et al. [16], Rabello et al. [27], and Suberviola et al. [6]. According to Polverino et al. [4], increased levels of biomarkers in HCAP patients up to 1 month after admission could reflect worse clinical conditions and poorer outcome of these patients. Also, Christ-Crain et al. [28] had explained this increase by different mechanisms; first, as a member of the Calc gene family, ADM is widely expressed and extensively synthesized during sepsis. Bacterial endotoxins and proinflammatory cytokines upregulate ADM gene expression in many tissues. Second, decreased clearance by the kidneys may be responsible for the increased level in sepsis. Third, an alternative site of proADM clearance may be the lung, and thus, in infection-related lung injury, impaired removal of proADM from pulmonary circulation results in increased proADM plasma levels.

Also, in our study, proADM levels showed a statistically significant increase in HCAP patients who died than that in survivors (Table 6). These higher levels in our study could be attributed to the fact that HCAP patients had more complications – for example, septic shock, empyema, and ARDS. Similar results were reported by Christ-Crain et al. [29], who found increased proADM levels in
nonsurviving septic patients than in the surviving group. Bello et al. [13] explained the relationship between high proADM levels and short-term survival as follows:

(1) Worse general condition is associated with lower immune function, thereby facilitating the spread of respiratory infection, and

(2) A more severe infection exacerbates the underlying chronic (cardiovascular or renal) disease of the patients.

To evaluate the potential to predict severity and also death from pneumonia in HCAP patients, ROC curves were constructed (Figs 1 and 2).

A serum proADM cut-off level more than 1.8 nmol/l had good sensitivity and PPV (91.7% for each) and high specificity and NPV (95% for each) in predicting severity of the disease among HCAP patients. However, a serum proADM cut-off level more than 2.9 nmol/l had very high sensitivity and NPV (100% for each), but low specificity (42.3%) and PPV (25%) in predicting mortality among those patients (Table 8). In agreement with our results, Renaud et al. [14] reported a cut-off value of 1.8 nmol/l of proADM in predicting early severe CAP and requirement for ICU admission with a sensitivity of 61.3% and a specificity of 76.9%. Another study carried out by Bello et al. [13] reported a lower cut-off level (0.646 and 0.833 nmol/l) of proADM in predicting severity and complications, respectively. This difference can be explained as follows:

(1) Use of the risk of early admission to ICU score (REA-ICU score) as the scoring system for CAP severity assessment and not CURB-65 scoring, and

(2) The study included immunocompetent CAP patients and not HCAP patients.

In contrast to our results, Christ-Crain et al. [28] reported that a lower level of serum proADM (1.8 nmol/l) was the optimal cut-off value to predict short-term mortality with a sensitivity of 80% and a specificity of 72%. This discrepancy may be because of patient selection as CAP patients with cystic fibrosis and severely immunocompromised patients were excluded from this study. However, in our study, a small number of patients with heterogeneous risk factors for HCAP were included.

ProADM improved both clinical risk scores and was superior for the prediction of serious complications. The incorporation of a combination of biomarkers reflecting systemic inflammation, endothelial dysfunction, stress, and cardiac function into the clinical risk scores improved their prognostic accuracy for the prediction of short-term complication rates [12].

**Conclusion**

HCAP patients show a more complicated in-hospital course of pneumonia, with worse outcome than CAP patients. Use of proADM as a novel biomarker enhances the performance of the CURB-65 scoring system for assessment of CAP and HCAP severity. In HCAP patients, serum proADM level more than 1.8 nmol/l can predict severity with good sensitivity (91.7%) and high specificity (95%), whereas serum proADM level more than 2.9 nmol/l can predict mortality with very high sensitivity (100%) and low specificity (42.3%).

**Acknowledgements**

Conflicts of interest

There are no conflicts of interest.

**References**

1. Carratala J, Mykietiuk A, Fernandez-Sabe N, et al. Healthcare-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy and clinical outcomes. *Arch Intern Med* 2007; 167:1393–1399.

2. Micek ST, Kollef KE, Reichley RM, et al. Healthcare-associated pneumonia and community-acquired pneumonia: a single center experience. *Antimicrob Agents Chemother* 2007; 51:3568–3573.

3. Attridge RT, Frei CR, Restrepo MI, et al. Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. *Eur Respir J* 2011; 38:879–887.

4. Polverino E, Cilloniz C, Esquinas C, et al. Healthcare-associated pneumonia (HCAP): clinical features and biomarkers. *Am J Respir Crit Care Med* 2010; 181:A3212.

5. Carrabba M, Zarattonello M, Bonara P, et al. Severity assessment of healthcare-associated pneumonia and pneumonia in immunosuppression. *Eur Respir J* 2012; 40:1201–1210.

6. Suberviola B, Castellanos-Ortega A, Llorca J, et al. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia. *Swiss Med Wkly* 2012; 142:w13542.

7. Chaimers JD. ICU admission and severity assessment in community-acquired pneumonia. *Crit Care Med* 2010; 38:1315–1316.

8. Michels M, Djamiatun K, Faradz SMH, et al. High plasma mid-regional proadrenomedullin levels in children with severe dengue virus infections. *J Clin Virol* 2011; 50:8–12.

9. Temmesfeld-Wollbruck B, Hocke AC, Sutto RP, et al. Adrenomedullin and endothelial barrier function. *Thromb Haemost* 2007; 98:944–951.

10. Alaker RP, Grosvenor PW, McNamara DC, et al. Mechanisms of adrenomedullin antimicrobial action. *Peptides* 2006; 27:661–666.

11. Yang S, Zhou M, Fowler DE, et al. Mechanisms of the beneficial effect of adrenomedullin and adrenomedullin-binding protein-1 in sepsis: down-regulation of proinflammatory cytokines. *Crit Care Med* 2002; 30:2729–2735.

12. Schuetz P, Wolbers M, Christ-Crain M, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. *Chest* 2010; 138:401–408.

13. Bello S, Lasieria AB, Minchole E, et al. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. *Eur Respir J* 2012; 39:1144–1155.

14. Renaud B, Schuetz P, Claessens YE, et al. Proadrenomedullin improves risk of early admission to ICU score for predicting early severe community-acquired pneumonia. *Chest* 2012; 142:1447–1454.

15. Polverino E, Torres A. Diagnostic strategies for healthcare-associated pneumonia. *Semin Respir Crit Care Med* 2009; 30:36–45.

16. Albrich WC, Dusemund F, Ruegger K, et al. Enhancement of CURB 65 score with proadrenomedullin (CURRB65-A) for outcome prediction in lower
respiratory tract infections. Derivation of a clinical algorithm. BMC Infect Dis 2011; 11:112–124.

17 Porstmann T, Kiessig ST. Enzyme immunoassay techniques: an overview. J Immunol Methods 1992; 150:5–21.

18 American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864–874.

19 Bernard GAR, Artigas KL, Brigham J, et al. The American European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trials coordination. Am J Respir Crit Care Med 1994; 149:818–824.

20 Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243–250.

21 Lim WS, Van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58:377–382.

22 Joong BH, Koh WJ, Yoo H, et al. Performances of prognostic scoring systems in patients with healthcare-associated pneumonia. Clin Infect Dis 2013; 56:625–632. Available at: http://cid.oxfordjournals.org.

23 Huang DT, Angus DC, Kellum JA, et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest 2009; 136:823–831.

24 Courtais C, Kuster N, Dupuy AM, et al. Proadrenomedullin, a useful tool for risk stratification in high pneumonia severity index score community-acquired pneumonia. Am J Emerg Med 2013; 31:215–221. Available at: http://dx.doi.org.

25 Widmer D, Drozdzov D, Ruegger K, et al. Effectiveness of proadrenomedullin enhanced CURB65 score algorithm in patients with community-acquired pneumonia in ‘real life’, an observational quality control survey. J Clin Med 2014; 3:267–279.

26 Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia free to view. Chest 2005; 128:3854–3862.

27 Rabello LSC, Pitrowsky MT, Soares M, et al. Novel biomarkers in severe community-acquired pneumonia. Rev Bras Ter Intensiva 2011; 23:499–506.

28 Christ-Crain M, Morgenthaler NG, Stolz D, et al. (2006): Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN4176397]. Available at: http://ccforum.com/content/10/3/R96.

29 Christ-Crain M, Morgenthaler NG, Struck J, et al. Mid-regional proadrenomedullin as a prognostic maker in sepsis: an observational study. Crit Care 2005; 9:R616–R624.